Investing in early-stage stem cell therapy developers

Stijn Heessen, Kristian Tryggvason

21 February 2025

Viewpoint

Gene delivery: persistent challenges call for a reference measure

Max Ryadnov

22 October 2024

Viewpoint

Regulatory strategies for developing and manufacturing RNA-LNPs

Alexander Aust

05 April 2024

Viewpoint

Following the (mAb) leader: leveraging monoclonal antibody cell line development & banking CMC strategies for iPSC-derived cell therapies

Damien Fink

17 January 2024

Viewpoint

The current viral vector characterization landscape: from navigating evolving regulatory guidance to leveraging analytical tools for process development

Ning Ding

08 December 2023

Viewpoint

Designing cell therapy analytics for future success

Raymond Luke

21 September 2023

Viewpoint

Preclinical safety assessment in therapeutic genome editing

Roberto Nitsch

10 March 2023

Viewpoint

Addressing gene therapy translational R&D bottlenecks in the CNS

Anindya Sen

09 March 2023

Viewpoint

Producing cell-based therapeutic products with lot-to-lot consistency from highly variable starting cell products

William E Janssen, Scott R Burger

02 November 2022

Viewpoint

Analytical development for rapid response vaccines: start early, think ahead

Anna Särnefält, Ingrid Kromann

20 May 2022

Viewpoint

Considerations for demonstrating comparability of AAV processes

Laura Giersch

26 April 2022

Viewpoint

Process analytical technology tools for process monitoring in CGT product manufacturing

Wai Lam W Ling, Arun C Patel

18 January 2022

Viewpoint

Recent evolution in Process Analytical Technology for viral vectors

Tony Bou Kheir

20 August 2021

Viewpoint